• Mashup Score: 0

    The National Kidney Foundation Serving Maryland & Delaware (NKFMDDE) is pleased to announce our Research Application Portal OPENS Monday, October 2, 2023 and closes on Monday, December 4, 2023 at 5:00pm. Over the years, the National Kidney Foundation has invested over $100 mil lion to support the treatment of kidney disease. Locally, the National Kidney Foundation Serving Maryland & Delaware (NKFMDDE) has been able to distribute over $3,500,000 over the last few decades for pilot projects and for those

    Tweet Tweets with this article
    • #FundingOpportunities from @NKFMDDE for #pilotprojects focused on different areas of #kidneydisease that will impact improvement in the care of patients through discovering novel mechanisms or management strategies. Apply by ๐Ÿ—“๏ธ Dec. 4! ๐Ÿ”— https://t.co/G6M5SOKMnx https://t.co/Q76DMr5fLo

  • Mashup Score: 0

    Slow walking pace and weight gain may be linked to chronic kidney disease risk in adults who have obesity but not diabetes, according to a study by Drexel University researchers. Results from the College of Medicine and Dornsife School of Public Health suggest staying fit and avoiding weight gain may be more pivotal than weight loss alone to reduce CKD risk.

    Tweet Tweets with this article
    • Slow walking pace and weight gain may be linked to chronic #kidneydisease risk in adults who have #obesity but not #diabetes, according to a study by @DrexelUniv researchers. https://t.co/hNQiKYMp04

  • Mashup Score: 0

    โ€œA doctor, like a writer, must have a voice of his own, something that conveys the timbre, the rhythm, the diction, and the music of his humanity, that compensates us for all the speechless machineโ€ฆ

    Tweet Tweets with this article
    • CALL FOR SUBMISSIONS: How has #kidneydisease impacted your life? Consider sharing your experience to our "In A Few Words" feature. We welcome submissions from patients/physicians/allied health professionals/family members. Details on the #AJKDBlog: https://t.co/fvCfyiBqIf https://t.co/iVgQOZengb

  • Mashup Score: 0

    Home > ESC Congress 2023 > Dr. Scott Solomon: Dapagliflozin Benefits Patients With Heart Failure, Kidney Disease A pooled analysis from the DELIVER and DAPA-HF trials assessed the efficacy of FARXIGA (dapagliflozin) in patients with heart failure and deteriorating kidney function. The findings, which demonstrated clinical benefit, were presented at the European Society of Cardiology Congress 2023. In this exclusive interview, DocWire News spoke with the presenting investigator, Dr. Scott Solomon, of

    Tweet Tweets with this article
    • Dr. Scott Solomon discussed a pooled analysis from the DELIVER and DAPA-HF trials which showed the clinical benefit of #dapagliflozin in patients with #heartfailure and deteriorating kidney function. #kidneydisease #ESCCongress #ESC2023 https://t.co/eh9toWDtwi https://t.co/7ydnh5ggaQ